nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

30.08.2023 | Editorial

Molecular imaging for better theranostics

verfasst von: Dawei Jiang, Weijun Wei

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2023

Einloggen, um Zugang zu erhalten

Excerpt

The ability to “see” has been a clinical necessity. Although the discovery of X-ray sparked the idea of seeing through and inside of our body and propelled the development of modern medicine, it was the advent of molecular imaging that has been driving the ongoing clinical shift toward individualized and precision healthcare [1, 2]. Nuclear medicine techniques, including positron emission tomography (PET) and single photon emission computed tomography (SPECT), enable us to appreciate the complex structural and molecular dynamics that play out in our bodies. The ability to see how drug molecules metabolize, to observe how biological processes progress, and to visualize how cells and organs function is an incredible leap forward in understanding human health and safeguarding it. …

James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92:897–965. https://doi.org/10.1152/physrev.00049.2010.CrossRefPubMed

Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. Early detection of cancer. Science. 2022;375:eaay040. https://doi.org/10.1126/science.aay9040.CrossRef

Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593:282–8. https://doi.org/10.1038/s41586-021-03442-1.CrossRefPubMedPubMedCentral

An S, Huang G, Liu J, Wei W. PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05905-7.CrossRefPubMed

Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 2021;48:4350–68. https://doi.org/10.1007/s00259-021-05433-w.CrossRefPubMedPubMedCentral

Privé BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06144-0.CrossRefPubMedPubMedCentral

Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;220749. https://doi.org/10.1148/radiol.220749.

Millul J, Koepke L, Haridas GR, Sparrer KMJ, Mansi R, Fani M. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06272-7.CrossRefPubMedPubMedCentral

Pang Y, Zhao L, Fang J, Chen J, Meng L, Sun L, et al. Development of FAPI tetramers to improve tumor uptake and efficacy of FAPI radioligand therapy. J Nucl Med. 2023. https://doi.org/10.2967/jnumed.123.265599.CrossRefPubMedPubMedCentral

10.

Zhao L, Niu B, Fang J, Pang Y, Li S, Xie C, et al. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of (68)Ga-labeled FAPI dimer. J Nucl Med. 2022;63:862–8. https://doi.org/10.2967/jnumed.121.263016.CrossRefPubMedPubMedCentral

11.

Konrad M, Rinscheid A, Wienand G, Nittbaur B, Wester H-J, Janzen T, et al. [99mTc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06395-x.CrossRefPubMed

12.

Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, et al. Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using (68)Ga-Pentixafor PET. J Nucl Med. 2022;63:1687–92. https://doi.org/10.2967/jnumed.121.263693.CrossRefPubMed

13.

Song W, Song Y, Li Q, Fan C, Lan X, Jiang D. Advances in aptamer-based nuclear imaging. Eur J Nucl Med Mol Imaging. 2022;49:2544–59. https://doi.org/10.1007/s00259-022-05782-0.CrossRefPubMed

14.

Wu Q, Yang S, Liu J, Jiang D, Wei W. Antibody theranostics in precision medicine. Med. 2023;4:69–74. https://doi.org/10.1016/j.medj.2023.01.001.CrossRefPubMed

15.

Wei W, Jiang D, Evangelista L, Cai W. Antibody-based imaging and therapy for precision medicine. Mol Pharm. 2022;19:3453–5. https://doi.org/10.1021/acs.molpharmaceut.2c00606.CrossRefPubMed

16.

Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120:3787–851. https://doi.org/10.1021/acs.chemrev.9b00738.CrossRefPubMedPubMedCentral

17.

Wang H, Liu Q, Lan X, Jiang D. Framework nucleic acids in nuclear medicine imaging: shedding light on nano-bio interactions. Angewandte Chemie (International ed in English). 2022;61:e202111980. https://doi.org/10.1002/anie.202111980.

18.

Li M, Wang S, Kong Q, Cheng X, Yan H, Xing Y, et al. Advances in macrocyclic chelators for positron emission tomography imaging. VIEW. 2023;20230042. https://doi.org/10.1002/VIW.20230042.

19.

Kwon SI, Ota R, Berg E, Hashimoto F, Nakajima K, Ogawa I, et al. Ultrafast timing enables reconstruction-free positron emission imaging. Nat Photonics. 2021;15:914–8. https://doi.org/10.1038/s41566-021-00871-2.CrossRefPubMedPubMedCentral

20.

Jung KO, Kim TJ, Yu JH, Rhee S, Zhao W, Ha B, et al. Whole-body tracking of single cells via positron emission tomography. Nat Biomed Eng. 2020;4:835–44. https://doi.org/10.1038/s41551-020-0570-5.CrossRefPubMedPubMedCentral

21.

Pratt EC, Lopez-Montes A, Volpe A, Crowley MJ, Carter LM, Mittal V, et al. Simultaneous quantitative imaging of two PET radiotracers via the detection of positron-electron annihilation and prompt gamma emissions. Nat Biomed Eng. 2023;7:1028–39. https://doi.org/10.1038/s41551-023-01060-y.CrossRefPubMed

22.

Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57:27–33. https://doi.org/10.2967/jnumed.115.162024.CrossRefPubMed

23.

Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, et al. Identification of HER2-positive metastases in patients with HER2-negative primary breast cancer by using HER2-targeted (89)Zr-Pertuzumab PET/CT. Radiology. 2020;296:370–8. https://doi.org/10.1148/radiol.2020192828.CrossRefPubMed

24.

Gondry O, Xavier C, Raes L, Heemskerk J, Devoogdt N, Everaert H, et al. Phase I study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT assessment of protumorigenic macrophage presence in solid tumors (MMR phase I). J Nucl Med. 2023. https://doi.org/10.2967/jnumed.122.264853.CrossRefPubMedPubMedCentral

25.

Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, et al. CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of (89)Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody. J Nucl Med. 2022;63:720–6. https://doi.org/10.2967/jnumed.121.262485.CrossRefPubMedPubMedCentral

26.

Stutvoet TS, van der Veen EL, Kol A, Antunes IF, de Vries EFJ, Hospers GAP, et al. Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET tracer (18)F-BMS-986192. J Nucl Med. 2020;61:1839–44. https://doi.org/10.2967/jnumed.119.241364.CrossRefPubMed

27.

Praetorius F, Leung PJY, Tessmer MH, Broerman A, Demakis C, Dishman AF, et al. Design of stimulus-responsive two-state hinge proteins. Science. 2023;381:754–60. https://doi.org/10.1126/science.adg7731.CrossRefPubMed

28.

Huppelschoten Y, Elhebieshy A, Hameed D, Sapmaz A, Buchardt J, Nielsen T, et al. Total chemical synthesis of a functionalized GFP nanobody. ChemBioChem. 2022. https://doi.org/10.1002/cbic.202200304.

29.

Hartmann L, Botzanowski T, Galibert M, Jullian M, Chabrol E, Zeder-Lutz G, et al. VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH. Protein Sci. 2019;28:1865–79. https://doi.org/10.1002/pro.3712.CrossRefPubMedPubMedCentral

30.

Noncanonical amino acids as doubly bio-orthogonal handles for one-pot preparation of protein multiconjugates. Nat Commun. 2023;14. https://doi.org/10.1038/s41467-023-36658-y.

31.

Klauser PC, Chopra S, Cao L, Bobba KN, Yu B, Seo Y, et al. Covalent proteins as targeted radionuclide therapies enhance antitumor effects. ACS Cent Sci. 2023;9:1241–51. https://doi.org/10.1021/acscentsci.3c00288.CrossRefPubMedPubMedCentral

32.

Yang E, Liu Q, Huang G, Liu J, Wei W. Engineering nanobodies for next-generation molecular imaging. Drug Discov Today. 2022;27:1622–38. https://doi.org/10.1016/j.drudis.2022.03.013.CrossRefPubMed

33.

Cheal SM, Chung SK, Vaughn BA, Cheung NV, Larson SM. Pretargeting: a path forward for radioimmunotherapy. J Nucl Med. 2022;63:1302–15. https://doi.org/10.2967/jnumed.121.262186.CrossRefPubMed

34.

Feng Y, Meshaw R, Zhao XG, Jannetti S, Vaidyanathan G, Zalutsky MR. Effective treatment of human breast carcinoma xenografts with single-dose (211)At-labeled Anti-HER2 single-domain antibody fragment. J Nucl Med. 2023;64:124–30. https://doi.org/10.2967/jnumed.122.264071.CrossRefPubMedPubMedCentral

35.

Abou DS, Longtine M, Fears A, Benabdallah N, Unnerstall R, Johnston H, et al. Evaluation of candidate theranostics for (227)Th/(89)Zr paired radioimmunotherapy of lymphoma. J Nucl Med. 2023;64:1062–8. https://doi.org/10.2967/jnumed.122.264979.CrossRefPubMedPubMedCentral

36.

Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S, Egusa EA, et al. Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy. Clin Cancer Res. 2023;29:1916–28. https://doi.org/10.1158/1078-0432.Ccr-22-3291.CrossRefPubMedPubMedCentral

37.

Ell P. 50 years EJNM and EJNMMI. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06361-7.CrossRef

Titel: Molecular imaging for better theranostics
verfasst von: Dawei Jiang
Weijun Wei
Publikationsdatum: 30.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06415-w

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Molecular imaging for better theranostics

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2023

Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis

Prevalence of ATTR-CA and high-risk features to guide testing in patients referred for TAVR

A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers

Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor

Feasibility of acquisitions using total-body PET/CT with a half-dose [68Ga]Ga-FAPI-04 activity in oncology patients

Variability of [18F]FDG-PET/LDCT reporting in vascular graft and endograft infection